{"id":"quinvaxem-in-uniject","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL5715933","moleculeType":null,"molecularWeight":"612.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified polysaccharide capsules from Haemophilus influenzae type b conjugated to protein carriers, along with inactivated pertussis toxin and other antigens, which are presented to the immune system to generate protective antibodies and T-cell mediated immunity. The Uniject delivery system is a pre-filled, single-dose injection device designed to improve vaccine administration in resource-limited settings. This combination approach provides simultaneous protection against five major childhood infectious diseases.","oneSentence":"Quinvaxem is a pentavalent conjugate vaccine that provides immunization against Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and hepatitis B through stimulation of humoral and cellular immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:00.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunization of infants and children against Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and hepatitis B"}]},"trialDetails":[{"nctId":"NCT01917357","phase":"PHASE3","title":"A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2013-09","conditions":"Diphtheria, Pertussis, Tetanus","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Quinvaxem in Uniject","genericName":"Quinvaxem in Uniject","companyName":"Crucell Holland BV","companyId":"crucell-holland-bv","modality":"Biologic","firstApprovalDate":"","aiSummary":"Quinvaxem in Uniject is a vaccine used to protect against Diphtheria, Pertussis, Tetanus, Hepatitis B, and Haemophilus infections. It is administered via Uniject, a single-dose injection device, as part of a Phase III clinical trial to compare its immunogenicity and safety with the same vaccine in single-dose vials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}